ReviewHelicobacter2015
Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography.
Review in Helicobacter, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Association of IL-10 promoter and IL-12 gene polymorphisms with the risk of symptomatic Helicobacter pylori infection.BMC gastroenterology · 2026Article
- HELICOBACTER PYLORI BEYOND THE STOMACH: WHEN THE STORY CHANGES.Arquivos de gastroenterologia · 2026Review
- Immune Thrombocytopenia Induced by Helicobacter pylori Infection: A Case Report and Literature Review.Cureus · 2025Article
- Article
- The chimeric UreB, FliD and Omp18 proteins for a sensitive and specific diagnosis ofIranian journal of microbiology · 2024Article
- Successful treatment of coexisting membranous nephropathy and immune thrombocytopenia by eradicating gastric Helicobacter pylori infection: a case report.CEN case reports · 2024Article
- Review
- Old and New Aspects ofChildren (Basel, Switzerland) · 2022Review
- Immune thrombocytopenic purpura secondary toProceedings (Baylor University. Medical Center) · 2022Article
- Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia.Science China. Life sciences · 2021Article
- Effect ofBlood research · 2021Article
- Helicobacter pylori metabolites exacerbate gastritis through C-type lectin receptors.The Journal of experimental medicine · 2021Article
- Review
- Article
- Molecular Mechanisms Contributing Bacterial Infections to the Incidence of Various Types of Cancer.Mediators of inflammation · 2020Review
- Identification of Candidate Biomarkers for Idiopathic Thrombocytopenic Purpura by Bioinformatics Analysis of Microarray Data.Iranian journal of pharmaceutical research : IJPR · 2020Article
- ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats.Journal of veterinary internal medicine · 2019Article
- Immune thrombocytopenic purpura.Journal of community hospital internal medicine perspectives · 2019Article
- Impact of Escherichia coli K12 and O18:K1 on human platelets: Differential effects on platelet activation, RNAs and proteins.Scientific reports · 2018Article
- Autoimmune Hepatitis with Concomitant Idiopathic Thrombocytopenic Purpura Diagnosed by Transjugular Liver Biopsy.Case reports in hepatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Idiopathic thrombocytopenic purpura (ITP) is typically a diagnosis of exclusion, assigned by clinicians after ruling out other identifiable etiologies. Since a report by Gasbarrini et al. in 1998, an accumulating body of evidence has proposed a pathophysiological link between ITP and chronic Helicobacter pylori (H. pylori) infection. Clinical reports have described a spontaneous resolution of ITP symptoms in about 50% of chronic ITP patients following empirical treatment of H. pylori infection, but response appears to be geography dependent. Studies have also documented that ITP patients in East Asian countries are more likely to express positive antibody titers against H. pylori-specific cytotoxic-associated gene A (CagA), a virulence factor that is associated with an increased risk for gastric diseases including carcinoma. While a definitive mechanism by which H. pylori may induce thrombocytopenia remains elusive, proposed pathways include molecular mimicry of CagA by host autoantibodies against platelet surface glycoproteins, as well as perturbations in the phagocytic activity of monocytes. Traditional treatments of ITP have been largely empirical, involving the use of immunosuppressive agents and immunoglobulin therapy. However, based on the findings of clinical reports emerging over the past 20 years, health organizations around the world increasingly suggest the detection and eradication of H. pylori as a treatment for ITP. Elucidating the exact molecular mechanisms of platelet activation in H. pylori-positive ITP patients, while considering biogeographical differences in response rates, could offer insight into how best to use clinical H. pylori eradication to treat ITP, but will require well-designed studies to confirm the suggested causative relationship between bacterial infection and an autoimmune disease state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.